PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Journal of Hepatology10.1016/s0168-8278(05)81882-3200542170470 HBeAg negative patients with chronic hepatitis B are less likely to have A biochemical breakthrough during lamivudine treatmenthttps://api.elsevier.com/content/article/PII:S0168827805818823?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827805818823?httpAccept=text/plain
Journal of Hepatology10.1016/s0168-8278(05)81916-6200542182504 Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis Bhttps://api.elsevier.com/content/article/PII:S0168827805819166?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827805819166?httpAccept=text/plain
Journal of Hepatology10.1016/s0168-8278(05)81922-1200542185510 HBsAg levels under interferon and lamivudine therapy in HBeAg-negative chronic hepatitis B (CHBe-) patientshttps://api.elsevier.com/content/article/PII:S0168827805819221?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827805819221?httpAccept=text/plain
Intervirology10.1159/0000749902003466344-349Viral Breakthrough during Lamivudine Therapy for Chronic Hepatitis BNancy Leunghttps://www.karger.com/Article/Pdf/74990, https://www.karger.com/Article/Pdf/74990
Hepatology10.1016/s0270-9139(03)81216-8200338723-7231178 Effect of the precore mutations on the HBEAG loss and viral breakthrough during lamivudine therapy in HBEAG-positive chronic hepatitis BS KIM, Y HWANG, K KWON, M JUNG, D PARK, O KWON, S KWON, Y KIM, Y KOO, Y KIMhttps://api.elsevier.com/content/article/PII:S0270913903812168?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0270913903812168?httpAccept=text/plain
Journal of Viral Hepatitis10.1111/j.1365-2893.2011.01542.x2011193220-226Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patientsR. Idilman, K. Cinar, G. Seven, Y. Bozkus, A. Elhan, M. Bozdayi, C. Yurdaydin, K. Baharhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2893.2011.01542.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2893.2011.01542.x/fullpdf
Yearbook of Gastroenterology10.1016/s0739-5930(08)70202-220072007253-255Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BG.A. Makarhttps://api.elsevier.com/content/article/PII:S0739593008702022?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0739593008702022?httpAccept=text/plain
Yearbook of Pediatrics10.1016/s0084-3954(08)70153-220072007276-278Entecavir Versus Lamivudine for Patients With HBeAg-Negative Chronic Hepatitis BJ.A. Stockmanhttps://api.elsevier.com/content/article/PII:S0084395408701532?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0084395408701532?httpAccept=text/plain
Yearbook of Medicine10.1016/s0084-3873(08)70051-82007200780-81Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BD.R. Snydmanhttps://api.elsevier.com/content/article/PII:S0084387308700518?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0084387308700518?httpAccept=text/plain
Hepatology10.1053/jhep.2001.272202001343583-589Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequencesC Liuhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2001.27220, https://onlinelibrary.wiley.com/doi/full/10.1053/jhep.2001.27220